New Breast Cancer Trial Results Show Potential
A study explores new pre-surgery drug combinations for those with HER2-low, hormone receptor-positive breast cancer.
Updated on Oct. 23, 2026 in Cancer
The phase 2 TALENT trial examined using the drug trastuzumab deruxtecan as a pre-surgery treatment for early-stage HER2-low, hormone receptor-positive breast cancer. Researchers evaluated three different treatment protocols, including combinations with chemotherapy and hormonal therapy, to determine their impact on tumor reduction before surgery.
Why it matters
Standard pre-surgery treatments are critical for improving outcomes in breast cancer, and this trial aimed to see if antibody-drug conjugates could provide a viable alternative or enhancement. These findings offer early insights for patients and physicians weighing new treatment pathways for high-risk early-stage disease.
This Phase 2 trial evaluated the neoadjuvant use of trastuzumab deruxtecan across three arms in patients with HER2-low, hormone receptor-positive breast cancer. Pathological complete response rates were 7%, 3%, and 9%, while objective response rates reached 62%, 66%, and 72% respectively.
The players
ESMO Congress
An annual international medical conference where oncologists and researchers present late-breaking clinical trial data.
Fred Hutchinson Cancer Center
A research institution in Seattle specializing in advanced cancer care, clinical trials, and patient advocacy.
The details
The trial tested trastuzumab deruxtecan as a single agent and in combination with the hormonal therapy anastrozole or subsequent chemotherapy. Researchers increased the treatment cycles from 6 to 8 after observing promising early responses, while men and premenopausal women received gonadotropin-releasing hormone as part of the combination protocol. Treatment-related adverse events of grade 3 or greater were reported in up to 28% of patients, and three cases of interstitial lung disease were observed.
Timeline
Results were presented from October 23-27, 2026, at the ESMO Congress in Madrid, Spain.
Health Landscape
This study follows the established trajectory of testing targeted antibody-drug conjugates within existing neoadjuvant breast cancer treatment standards. It provides a necessary update on how these therapies perform compared to traditional chemotherapy in specific genetic subtypes.
These findings are strictly preliminary and do not indicate a change in current surgical or chemotherapy protocols for breast cancer patients. Individuals with HER2-low breast cancer should consult their oncologists to understand how ongoing trial results may eventually influence future care options.
The takeaway
The TALENT trial provides an early look at how new antibody-based therapies perform as pre-surgery treatments for specific breast cancer subtypes. Patients interested in the latest clinical research should ask their oncology teams about active trials or studies regarding neoadjuvant therapy.
Further reading
Learn more about evolving Cancer treatment research.
